Back to search results

Study of Lifestyle and Senolytic Treatments for Obesity in Older Adults

This study is looking at how lifestyle changes and specific medications affect fat cells in older adults with obesity. Researchers want to understand how exercise and drugs like Dasatinib and Quercetin impact your body's metabolism (how your body uses energy) and insulin sensitivity (how well your body responds to insulin). You could be eligible if you are an adult aged 18-30 who is lean or obese, or an older adult (65+) with obesity. The study aims to see if these interventions can improve how your body handles sugar and insulin. The current recruitment status is unclear, but 160 participants are planned.

Study design
This is an interventional study with 160 planned participants. Older obese participants will be randomly assigned to one of three groups: a lifestyle intervention, Dasatinib and Quercetin, or a placebo.
What's involved
You will undergo baseline biopsies of abdominal fat tissue, glucose tolerance testing, and wear an accelerometer for 7 days. You will also use a smartphone app to record your food intake for 7 days and have body composition scans. Only older obese participants will continue with the randomized interventions for approximately 10 consecutive weeks.
Compensation
Not stated in the trial record.
Follow-up
Insulin sensitivity will be measured at Week 4 and Week 15, and glucose tolerance will be measured from Baseline to Week 14.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05653258

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

Recruiting
PHASE2Ages 18+InterventionalTreatment
Cedars-Sinai Medical Center
~160 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Lifestyle InterventionDasatinib 100 MGQuercetin 1000mgPlaceboAbdominal adipose tissue biopsy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Insulin sensitivity
Measured over Week 4 and Week 15
+1 more outcome measured

Conditions

Obesity
Healthy Lifestyle

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Nicolas Musi, MD · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center

Who to contact

Nicolas Musi, MD
[email protected]
210-562-6140
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

impaired kidney function (eGFR \< 30ml/min/1.73m² as calculated by the CKD-EPI equation);
impaired liver function (AST or ALT level \> 2 times upper limit of normal (ULN);
total Bilirubin level \> 1.5 times ULN;
TSH \> 1.5 times ULN or \< lower limit of normal (LLN);
Hemoglobin \<10.0 g/dl; Platelets \<125,000 cell/mm³;
Platelets \< 125,000 cell/mm³
Prothrombin time (PT) \> 1.0 times ULN
Partial prothrombin time (PTT) \> 1.0 times ULN. 7. Active gastrointestinal disease; coagulopathy; GI bleed within 6 months 8. Clinically significant heart disease (e.g. NYH Classification \>II; ischemia) 9. Peripheral vascular disease (claudication) 10. QTc prolongation \>45 msec 11. Use of anti-arrhythmic medications known to cause QTc prolongation, anti-platelet or anti-coagulant medication (see section 5.3) 12. Use of quinolone antibiotics or any other drugs that may prolong the QTc interval (see section 5.3) 13. Pulmonary disease (COPD), severe asthma or exercise-induced asthma 14. Recent systemic or pulmonary embolus 15. Uncontrolled blood pressure (systolic BP\>170, diastolic BP\>95 mmHg) 16. Smoking, alcohol use (history of regular alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male participants. 1 drink = 5 ounces \[150ml\] of wine or 12 ounces \[360ml\] of beer or 1.5 ounces \[45ml\] of hard liquor) or recreational drug use (other than marijuana) 17. Pregnant or breastfeeding 18. Postmenopausal women new (within 6 months) to systemic hormone replacement therapy 19. Previous bariatric surgery 20. History of stroke with motor disability 21. Recent (3 years) treated cancer other than basal cell carcinoma 22. Acute or chronic infection 23. Medication that might interfere with metabolic studies (weight loss medication, systemic steroids, immunosuppressants) within 6 months (see section 5.3) 24. Potentially senolytic agents within the last 6 months: fisetin, quercetin, luteolin, dasatinib, piperlongumine, or navitoclax (see section 5.3) 25. History of allergy to dasatinib, quercetin and/or lidocaine. 26. Concurrent enrollment in another interventional trial.

What this trial measures

  • Insulin sensitivityWeek 4 and Week 15

    Change in skeletal muscle insulin sensitivity

  • Glucose toleranceBaseline to Week 14

    Measurement of change in glucose tolerance using a glucose tolerance test